Dinutuximab con quimioterapia, cirugía y trasplante de células madre para el tratamiento de niños con neuroblastoma de alto riesgo recién diagnosticado
Un estudio de fase 3 de dinutuximab agregado a la terapia multimodal intensiva para niños con neuroblastoma de alto riesgo recién diagnosticado
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
- Droga: Carboplatin
- Droga: Cyclophosphamide
- Droga: Cisplatin
- Procedimiento: Bone Marrow Biopsy
- Droga: Doxorubicin
- Droga: Vincristine
- Procedimiento: Magnetic Resonance Imaging
- Procedimiento: Echocardiography Test
- Procedimiento: Multigated Acquisition Scan
- Procedimiento: Bone Marrow Aspiration
- Droga: Etoposide
- Procedimiento: Computed Tomography
- Droga: Topotecan
- Radiación: Radiation Therapy
- Procedimiento: Biospecimen Collection
- Otro: Survey Administration
- Droga: Melphalan
- Droga: Irinotecan
- Droga: Thiotepa
- Biológico: Dinutuximab
- Procedimiento: FDG-Positron Emission Tomography and Computed Tomography Scan
- Procedimiento: Hematopoietic Cell Transplantation
- Droga: Isotretinoin
- Procedimiento: Leukapheresis
- Procedimiento: Radionuclide Imaging
- Droga: Temozolomide
- Procedimiento: Tumor Resection
Descripción detallada
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Reclutamiento
- Sydney Children's Hospital
-
Investigador principal:
- Draga Barbaric
-
Contacto:
- Site Public Contact
- Número de teléfono: (02) 9382-1721
-
Westmead, New South Wales, Australia, 2145
- Reclutamiento
- The Children's Hospital at Westmead
-
Contacto:
- Site Public Contact
- Número de teléfono: 61-2-9845 1400
-
Investigador principal:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Reclutamiento
- Queensland Children's Hospital
-
Investigador principal:
- Steven A. Foresto
-
Contacto:
- Site Public Contact
- Número de teléfono: 61 7 3068 1111
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Reclutamiento
- Royal Children's Hospital
-
Investigador principal:
- Martin A. Campbell
-
Contacto:
- Site Public Contact
- Número de teléfono: 61 3 9345 5656
- Correo electrónico: Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, Australia, 6009
- Reclutamiento
- Perth Children's Hospital
-
Contacto:
- Site Public Contact
- Correo electrónico: helpdesk@childrensoncologygroup.org
-
Investigador principal:
- Michelle Ng
-
-
-
-
-
Québec, Canadá, G1V 4G2
- Reclutamiento
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Investigador principal:
- Bruno Michon
-
Contacto:
- Site Public Contact
- Número de teléfono: 418-525-4444
- Correo electrónico: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canadá, T3B 6A8
- Reclutamiento
- Alberta Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 403-220-6898
- Correo electrónico: research4kids@ucalgary.ca
-
Investigador principal:
- Victor A. Lewis
-
Edmonton, Alberta, Canadá, T6G 2B7
- Reclutamiento
- University of Alberta Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 780-407-8798
- Correo electrónico: pedsoncologyresearch@ahs.ca
-
Investigador principal:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6H 3V4
- Reclutamiento
- British Columbia Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 6477 604-875-2345
-
Investigador principal:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 0V9
- Reclutamiento
- CancerCare Manitoba
-
Contacto:
- Site Public Contact
- Número de teléfono: 866-561-1026
- Correo electrónico: ctu_web@cancercare.mb.ca
-
Investigador principal:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canadá, A1B 3V6
- Reclutamiento
- Janeway Child Health Centre
-
Investigador principal:
- Lisa A. Goodyear
-
Contacto:
- Site Public Contact
- Número de teléfono: 709-777-8727
- Correo electrónico: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3K 6R8
- Reclutamiento
- IWK Health Centre
-
Contacto:
- Site Public Contact
- Número de teléfono: 902-470-8520
- Correo electrónico: Research@iwk.nshealth.ca
-
Investigador principal:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 3Z5
- Reclutamiento
- McMaster Children's Hospital at Hamilton Health Sciences
-
Contacto:
- Site Public Contact
- Número de teléfono: 905-521-2100
-
Investigador principal:
- Uma H. Athale
-
London, Ontario, Canadá, N6A 5W9
- Reclutamiento
- Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 519-685-8306
-
Investigador principal:
- Shayna M. Zelcer
-
Ottawa, Ontario, Canadá, K1H 8L1
- Reclutamiento
- Children's Hospital of Eastern Ontario
-
Contacto:
- Site Public Contact
- Número de teléfono: 613-737-7600
-
Investigador principal:
- Donna L. Johnston
-
Toronto, Ontario, Canadá, M5G 1X8
- Reclutamiento
- Hospital for Sick Children
-
Contacto:
- Site Public Contact
- Número de teléfono: 416-813-7654
- Correo electrónico: ask.CRS@sickkids.ca
-
Investigador principal:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal, Quebec, Canadá, H3H 1P3
- Reclutamiento
- The Montreal Children's Hospital of the MUHC
-
Contacto:
- Site Public Contact
- Número de teléfono: 514-412-4445
- Correo electrónico: info@thechildren.com
-
Investigador principal:
- Stephanie Mourad
-
Montreal, Quebec, Canadá, H3T 1C5
- Reclutamiento
- Centre Hospitalier Universitaire Sainte-Justine
-
Investigador principal:
- Monia Marzouki
-
Contacto:
- Site Public Contact
- Número de teléfono: 514-345-4931
- Correo electrónico: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canadá, J1H 5N4
- Reclutamiento
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contacto:
- Site Public Contact
- Número de teléfono: 819-820-6480
- Correo electrónico: crcinformation.chus@ssss.gouv.qc.ca
-
Investigador principal:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7N 0W8
- Reclutamiento
- Jim Pattison Children's Hospital
-
Investigador principal:
- Kathleen Felton
-
Contacto:
- Site Public Contact
- Número de teléfono: 306-655-3544
- Correo electrónico: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Reclutamiento
- Children's Hospital of Alabama
-
Contacto:
- Site Public Contact
- Número de teléfono: 205-638-9285
- Correo electrónico: oncologyresearch@peds.uab.edu
-
Investigador principal:
- Elizabeth D. Alva
-
Mobile, Alabama, Estados Unidos, 36604
- Reclutamiento
- USA Health Strada Patient Care Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-388-8721
-
Investigador principal:
- Hamayun Imran
-
-
Arizona
-
Mesa, Arizona, Estados Unidos, 85202
- Reclutamiento
- Banner Children's at Desert
-
Contacto:
- Site Public Contact
- Número de teléfono: 480-412-3100
-
Investigador principal:
- Joseph C. Torkildson
-
Phoenix, Arizona, Estados Unidos, 85016
- Reclutamiento
- Phoenix Childrens Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 602-546-0920
-
Investigador principal:
- Alok K. Kothari
-
Tucson, Arizona, Estados Unidos, 85719
- Reclutamiento
- Banner University Medical Center - Tucson
-
Contacto:
- Site Public Contact
- Correo electrónico: UACC-IIT@uacc.arizona.edu
-
Investigador principal:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72202-3591
- Reclutamiento
- Arkansas Children's Hospital
-
Investigador principal:
- Michael W. Bishop
-
Contacto:
- Site Public Contact
- Número de teléfono: 501-364-7373
-
-
California
-
Downey, California, Estados Unidos, 90242
- Reclutamiento
- Kaiser Permanente Downey Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 626-564-3455
-
Investigador principal:
- Robert M. Cooper
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- City of Hope Comprehensive Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-826-4673
- Correo electrónico: becomingapatient@coh.org
-
Investigador principal:
- Hung C. Tran
-
Loma Linda, California, Estados Unidos, 92354
- Reclutamiento
- Loma Linda University Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 909-558-4050
-
Investigador principal:
- Albert Kheradpour
-
Long Beach, California, Estados Unidos, 90806
- Reclutamiento
- Miller Children's and Women's Hospital Long Beach
-
Contacto:
- Site Public Contact
- Número de teléfono: 562-933-5600
-
Investigador principal:
- Jacqueline N. Casillas
-
Los Angeles, California, Estados Unidos, 90027
- Reclutamiento
- Children's Hospital Los Angeles
-
Contacto:
- Site Public Contact
- Número de teléfono: 323-361-4110
-
Investigador principal:
- Araz Marachelian
-
Los Angeles, California, Estados Unidos, 90048
- Reclutamiento
- Cedars-Sinai Medical Center
-
Investigador principal:
- Fataneh (Fae) Majlessipour
-
Contacto:
- Site Public Contact
- Número de teléfono: 310-423-2133
- Correo electrónico: Cancer.trial.info@cshs.org
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- Mattel Children's Hospital UCLA
-
Contacto:
- Site Public Contact
- Número de teléfono: 310-825-6708
-
Investigador principal:
- Satiro N. De Oliveira
-
Madera, California, Estados Unidos, 93636
- Reclutamiento
- Valley Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 559-353-3000
- Correo electrónico: Research@valleychildrens.org
-
Investigador principal:
- Ruetima Titapiwatanakun
-
Oakland, California, Estados Unidos, 94611
- Reclutamiento
- Kaiser Permanente-Oakland
-
Contacto:
- Site Public Contact
- Número de teléfono: 877-642-4691
- Correo electrónico: Kpoct@kp.org
-
Investigador principal:
- Aarati V. Rao
-
Oakland, California, Estados Unidos, 94609
- Reclutamiento
- UCSF Benioff Children's Hospital Oakland
-
Investigador principal:
- Jennifer G. Michlitsch
-
Contacto:
- Site Public Contact
- Número de teléfono: 510-428-3264
- Correo electrónico: PedOncRschOAK@ucsf.edu
-
Orange, California, Estados Unidos, 92868
- Reclutamiento
- Children's Hospital of Orange County
-
Contacto:
- Site Public Contact
- Número de teléfono: 714-509-8646
- Correo electrónico: oncresearch@choc.org
-
Investigador principal:
- Elyssa M. Rubin
-
Palo Alto, California, Estados Unidos, 94304
- Reclutamiento
- Lucile Packard Children's Hospital Stanford University
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-694-0012
- Correo electrónico: ccto-office@stanford.edu
-
Investigador principal:
- Jay Michael S. Balagtas
-
Sacramento, California, Estados Unidos, 95817
- Reclutamiento
- University of California Davis Comprehensive Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 916-734-3089
-
Investigador principal:
- Marcio H. Malogolowkin
-
Sacramento, California, Estados Unidos, 95816
- Reclutamiento
- Sutter Medical Center Sacramento
-
Contacto:
- Site Public Contact
- Correo electrónico: clinicalresearch@sutterhealth.org
-
Investigador principal:
- Sandra Baril
-
San Diego, California, Estados Unidos, 92123
- Reclutamiento
- Rady Children's Hospital - San Diego
-
Contacto:
- Site Public Contact
- Número de teléfono: 858-966-5934
-
Investigador principal:
- William D. Roberts
-
San Francisco, California, Estados Unidos, 94158
- Reclutamiento
- UCSF Medical Center-Mission Bay
-
Contacto:
- Site Public Contact
- Número de teléfono: 877-827-3222
- Correo electrónico: cancertrials@ucsf.edu
-
Investigador principal:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- Children's Hospital Colorado
-
Investigador principal:
- Navin R. Pinto
-
Contacto:
- Site Public Contact
- Número de teléfono: 303-764-5056
- Correo electrónico: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- Reclutamiento
- Connecticut Children's Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 860-545-9981
-
Investigador principal:
- Michael S. Isakoff
-
New Haven, Connecticut, Estados Unidos, 06520
- Reclutamiento
- Yale University
-
Contacto:
- Site Public Contact
- Número de teléfono: 203-785-5702
- Correo electrónico: canceranswers@yale.edu
-
Investigador principal:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, Estados Unidos, 19803
- Reclutamiento
- Alfred I duPont Hospital for Children
-
Contacto:
- Site Public Contact
- Número de teléfono: 302-651-5572
- Correo electrónico: Allison.bruce@nemours.org
-
Investigador principal:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Reclutamiento
- Children's National Medical Center
-
Investigador principal:
- Jeffrey S. Dome
-
Contacto:
- Site Public Contact
- Número de teléfono: 202-476-2800
- Correo electrónico: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33316
- Reclutamiento
- Broward Health Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 302-651-5572
- Correo electrónico: Allison.bruce@nemours.org
-
Investigador principal:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, Estados Unidos, 33908
- Reclutamiento
- Golisano Children's Hospital of Southwest Florida
-
Contacto:
- Site Public Contact
- Número de teléfono: 239-343-5333
- Correo electrónico: molly.arnstrom@leehealth.org
-
Investigador principal:
- Emad K. Salman
-
Gainesville, Florida, Estados Unidos, 32610
- Reclutamiento
- UF Health Cancer Institute - Gainesville
-
Contacto:
- Site Public Contact
- Número de teléfono: 352-273-8010
- Correo electrónico: cancer-center@ufl.edu
-
Investigador principal:
- Brian Stover
-
Hollywood, Florida, Estados Unidos, 33021
- Reclutamiento
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 954-265-1847
- Correo electrónico: OHR@mhs.net
-
Investigador principal:
- Iftikhar Hanif
-
Jacksonville, Florida, Estados Unidos, 32207
- Reclutamiento
- Nemours Children's Clinic-Jacksonville
-
Contacto:
- Site Public Contact
- Número de teléfono: 302-651-5572
- Correo electrónico: Allison.bruce@nemours.org
-
Investigador principal:
- Sridhi Patel
-
Miami, Florida, Estados Unidos, 33155
- Reclutamiento
- Nicklaus Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 888-624-2778
-
Investigador principal:
- Ziad A. Khatib
-
Miami, Florida, Estados Unidos, 33136
- Reclutamiento
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 305-243-2647
-
Investigador principal:
- Meghan McCormick
-
Orlando, Florida, Estados Unidos, 32806
- Reclutamiento
- Arnold Palmer Hospital for Children
-
Contacto:
- Site Public Contact
- Número de teléfono: 321-841-5357
- Correo electrónico: Jennifer.spinelli@orlandohealth.com
-
Investigador principal:
- Zhongbo Hu
-
Orlando, Florida, Estados Unidos, 32827
- Reclutamiento
- Nemours Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 302-651-5572
- Correo electrónico: Allison.bruce@nemours.org
-
Investigador principal:
- Sridhi Patel
-
Orlando, Florida, Estados Unidos, 32803
- Reclutamiento
- AdventHealth Orlando
-
Contacto:
- Site Public Contact
- Número de teléfono: 407-303-2090
- Correo electrónico: FH.Cancer.Research@flhosp.org
-
Investigador principal:
- Fouad M. Hajjar
-
St. Petersburg, Florida, Estados Unidos, 33701
- Reclutamiento
- Johns Hopkins All Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 727-767-4784
- Correo electrónico: Ashley.Repp@jhmi.edu
-
Investigador principal:
- Jennifer B. Dean
-
West Palm Beach, Florida, Estados Unidos, 33407
- Reclutamiento
- Saint Mary's Medical Center
-
Investigador principal:
- Matthew D. Ramirez
-
Contacto:
- Site Public Contact
- Número de teléfono: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Reclutamiento
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Investigador principal:
- William T. Cash
-
Contacto:
- Site Public Contact
- Número de teléfono: 404-785-0232
- Correo electrónico: Olivia.Floyd@choa.org
-
Savannah, Georgia, Estados Unidos, 31404
- Reclutamiento
- Memorial Health University Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 912-350-7887
- Correo electrónico: Lorraine.OHara@hcahealthcare.com
-
Investigador principal:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96826
- Reclutamiento
- Kapiolani Medical Center for Women and Children
-
Contacto:
- Site Public Contact
- Número de teléfono: 808-983-6090
-
Investigador principal:
- Wade T. Kyono
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Lurie Children's Hospital-Chicago
-
Contacto:
- Site Public Contact
- Número de teléfono: 773-880-4562
-
Investigador principal:
- Elizabeth A. Sokol
-
Chicago, Illinois, Estados Unidos, 60637
- Reclutamiento
- University of Chicago Comprehensive Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 773-702-8222
- Correo electrónico: cancerclinicaltrials@bsd.uchicago.edu
-
Investigador principal:
- Ami V. Desai
-
Chicago, Illinois, Estados Unidos, 60612
- Reclutamiento
- University of Illinois
-
Contacto:
- Site Public Contact
- Número de teléfono: 312-355-3046
-
Investigador principal:
- Dipti S. Dighe
-
Oak Lawn, Illinois, Estados Unidos, 60453
- Reclutamiento
- Advocate Children's Hospital-Oak Lawn
-
Contacto:
- Site Public Contact
- Número de teléfono: 847-723-7570
-
Investigador principal:
- Rebecca E. McFall
-
Park Ridge, Illinois, Estados Unidos, 60068
- Reclutamiento
- Advocate Children's Hospital-Park Ridge
-
Contacto:
- Site Public Contact
- Correo electrónico: helpdesk@childrensoncologygroup.org
-
Investigador principal:
- Rebecca E. McFall
-
Peoria, Illinois, Estados Unidos, 61637
- Reclutamiento
- OSF Children's Hospital of Illinois
-
Investigador principal:
- Prerna Kumar
-
Contacto:
- Site Public Contact
- Número de teléfono: 309-624-4945
- Correo electrónico: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, Estados Unidos, 62702
- Reclutamiento
- Southern Illinois University School of Medicine
-
Contacto:
- Site Public Contact
- Número de teléfono: 217-545-7929
-
Investigador principal:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Reclutamiento
- Riley Hospital for Children
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-248-1199
-
Investigador principal:
- Marissa Just
-
Indianapolis, Indiana, Estados Unidos, 46260
- Reclutamiento
- Ascension Saint Vincent Indianapolis Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 317-338-2194
- Correo electrónico: research@stvincent.org
-
Investigador principal:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Estados Unidos, 50309
- Reclutamiento
- Blank Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 515-241-8912
- Correo electrónico: samantha.mallory@unitypoint.org
-
Investigador principal:
- Samantha L. Mallory
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa/Holden Comprehensive Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-237-1225
-
Investigador principal:
- Andrew P. Groves
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Reclutamiento
- Wesley Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 316-962-7802
- Correo electrónico: WesleyResearch@wesleymc.com
-
Investigador principal:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- Reclutamiento
- University of Kentucky/Markey Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 859-257-3379
-
Investigador principal:
- James T. Badgett
-
Louisville, Kentucky, Estados Unidos, 40202
- Reclutamiento
- Norton Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 502-629-5500
- Correo electrónico: CancerResource@nortonhealthcare.org
-
Investigador principal:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70118
- Reclutamiento
- Children's Hospital New Orleans
-
Investigador principal:
- Maria C. Velez-Yanguas
-
Contacto:
- Site Public Contact
- Número de teléfono: 504-894-5377
-
-
Maine
-
Bangor, Maine, Estados Unidos, 04401
- Reclutamiento
- Eastern Maine Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 207-973-4274
-
Investigador principal:
- Daniel L. Callaway
-
Scarborough, Maine, Estados Unidos, 04074
- Reclutamiento
- Maine Children's Cancer Program
-
Investigador principal:
- Sei-Gyung K. Sze
-
Contacto:
- Site Public Contact
- Número de teléfono: 207-396-8670
- Correo electrónico: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Reclutamiento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Investigador principal:
- Allen R. Chen
-
Contacto:
- Site Public Contact
- Número de teléfono: 410-955-8804
- Correo electrónico: jhcccro@jhmi.edu
-
Baltimore, Maryland, Estados Unidos, 21215
- Reclutamiento
- Sinai Hospital of Baltimore
-
Investigador principal:
- Jason M. Fixler
-
Contacto:
- Site Public Contact
- Número de teléfono: 410-601-9083
-
Baltimore, Maryland, Estados Unidos, 21201
- Reclutamiento
- University of Maryland/Greenebaum Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-888-8823
-
Investigador principal:
- Teresa A. York
-
Bethesda, Maryland, Estados Unidos, 20889-5600
- Reclutamiento
- Walter Reed National Military Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 301-319-2100
-
Investigador principal:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Reclutamiento
- Massachusetts General Hospital Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 877-726-5130
-
Investigador principal:
- Lauren H. Boal
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Dana-Farber Cancer Institute
-
Contacto:
- Site Public Contact
- Número de teléfono: 877-442-3324
-
Investigador principal:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- C S Mott Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-865-1125
-
Investigador principal:
- Rajen Mody
-
Detroit, Michigan, Estados Unidos, 48201
- Suspendido
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Reclutamiento
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 616-391-1230
- Correo electrónico: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Reclutamiento
- Bronson Methodist Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 616-391-1230
- Correo electrónico: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Estados Unidos, 48073
- Reclutamiento
- Corewell Health Children's
-
Contacto:
- Site Public Contact
- Número de teléfono: 248-551-7695
-
Investigador principal:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- Reclutamiento
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Investigador principal:
- Michael K. Richards
-
Contacto:
- Site Public Contact
- Número de teléfono: 612-813-5913
- Correo electrónico: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Reclutamiento
- University of Minnesota/Masonic Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 612-624-2620
-
Investigador principal:
- Robin L. Williams
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Mayo Clinic in Rochester
-
Contacto:
- Site Public Contact
- Número de teléfono: 855-776-0015
-
Investigador principal:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- Reclutamiento
- University of Mississippi Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 601-815-6700
-
Investigador principal:
- Amanda Strobel
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65212
- Reclutamiento
- University of Missouri Children's Hospital
-
Investigador principal:
- Barbara A. Gruner
-
Contacto:
- Site Public Contact
- Número de teléfono: 573-882-1960
- Correo electrónico: snwq62@health.missouri.edu
-
Kansas City, Missouri, Estados Unidos, 64108
- Reclutamiento
- Children's Mercy Hospitals and Clinics
-
Investigador principal:
- Keith J. August
-
Contacto:
- Site Public Contact
- Número de teléfono: 816-302-6808
- Correo electrónico: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School of Medicine
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-600-3606
- Correo electrónico: info@siteman.wustl.edu
-
Investigador principal:
- Frederick S. Huang
-
St Louis, Missouri, Estados Unidos, 63141
- Reclutamiento
- Mercy Hospital Saint Louis
-
Contacto:
- Site Public Contact
- Número de teléfono: 314-251-7066
-
Investigador principal:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68114
- Reclutamiento
- Children's Hospital and Medical Center of Omaha
-
Contacto:
- Site Public Contact
- Número de teléfono: 402-955-3949
-
Investigador principal:
- Jill C. Beck
-
Omaha, Nebraska, Estados Unidos, 68198
- Reclutamiento
- University of Nebraska Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 402-559-6941
- Correo electrónico: unmcrsa@unmc.edu
-
Investigador principal:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89135
- Reclutamiento
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Contacto:
- Site Public Contact
- Número de teléfono: 702-384-0013
- Correo electrónico: research@sncrf.org
-
Investigador principal:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Reclutamiento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Investigador principal:
- Angela Ricci
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-639-6918
- Correo electrónico: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Reclutamiento
- Hackensack University Medical Center
-
Investigador principal:
- Katharine Offer
-
Contacto:
- Site Public Contact
- Número de teléfono: 551-996-2897
-
Morristown, New Jersey, Estados Unidos, 07960
- Reclutamiento
- Morristown Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 973-971-5900
-
Investigador principal:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Reclutamiento
- Saint Peter's University Hospital
-
Investigador principal:
- Nibal A. Zaghloul
-
Contacto:
- Site Public Contact
- Número de teléfono: 732-745-8600
- Correo electrónico: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Reclutamiento
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 732-235-8675
-
Investigador principal:
- Nehal S. Parikh
-
Newark, New Jersey, Estados Unidos, 07112
- Reclutamiento
- Newark Beth Israel Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 973-926-7230
- Correo electrónico: Christine.Kosmides@rwjbh.org
-
Investigador principal:
- Teena Bhatla
-
Paterson, New Jersey, Estados Unidos, 07503
- Reclutamiento
- Saint Joseph's Regional Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 973-754-2207
- Correo electrónico: HallL@sjhmc.org
-
Investigador principal:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- Suspendido
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Reclutamiento
- Albany Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 518-262-5513
-
Investigador principal:
- Lauren R. Weintraub
-
Buffalo, New York, Estados Unidos, 14263
- Reclutamiento
- Roswell Park Cancer Institute
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-767-9355
- Correo electrónico: askroswell@roswellpark.org
-
Investigador principal:
- Clare J. Twist
-
Mineola, New York, Estados Unidos, 11501
- Reclutamiento
- NYU Langone Hospital - Long Island
-
Contacto:
- Site Public Contact
- Número de teléfono: 212-263-4432
- Correo electrónico: cancertrials@nyulangone.org
-
Investigador principal:
- Chana L. Glasser
-
New Hyde Park, New York, Estados Unidos, 11040
- Reclutamiento
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Contacto:
- Site Public Contact
- Número de teléfono: 718-470-3460
-
Investigador principal:
- Julie I. Krystal
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Investigador principal:
- Nobuko Hijiya
-
Contacto:
- Site Public Contact
- Número de teléfono: 212-342-5162
- Correo electrónico: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Investigador principal:
- Elizabeth A. Raetz
-
Contacto:
- Site Public Contact
- Correo electrónico: CancerTrials@nyulangone.org
-
Rochester, New York, Estados Unidos, 14642
- Reclutamiento
- University of Rochester
-
Contacto:
- Site Public Contact
- Número de teléfono: 585-275-5830
-
Investigador principal:
- Rafi R. Kazi
-
Syracuse, New York, Estados Unidos, 13210
- Reclutamiento
- State University of New York Upstate Medical University
-
Contacto:
- Site Public Contact
- Número de teléfono: 315-464-5476
-
Investigador principal:
- Melanie A. Comito
-
The Bronx, New York, Estados Unidos, 10467
- Reclutamiento
- Montefiore Medical Center - Moses Campus
-
Contacto:
- Site Public Contact
- Número de teléfono: 718-379-6866
- Correo electrónico: eskwak@montefiore.org
-
Investigador principal:
- Alice Lee
-
Valhalla, New York, Estados Unidos, 10595
- Reclutamiento
- New York Medical College
-
Contacto:
- Site Public Contact
- Número de teléfono: 914-594-3794
-
Investigador principal:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801
- Reclutamiento
- Mission Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 828-213-7055
- Correo electrónico: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Investigador principal:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Reclutamiento
- UNC Lineberger Comprehensive Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 877-668-0683
- Correo electrónico: cancerclinicaltrials@med.unc.edu
-
Investigador principal:
- Thomas B. Alexander
-
Charlotte, North Carolina, Estados Unidos, 28203
- Reclutamiento
- Carolinas Medical Center/Levine Cancer Institute
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-804-9376
-
Investigador principal:
- Joel A. Kaplan
-
Charlotte, North Carolina, Estados Unidos, 28204
- Reclutamiento
- Novant Health Presbyterian Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 980-201-6360
- Correo electrónico: kashah@novanthealth.org
-
Investigador principal:
- Holly Edington
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University Medical Center
-
Investigador principal:
- Jessica M. Sun
-
Contacto:
- Site Public Contact
- Número de teléfono: 888-275-3853
-
Greenville, North Carolina, Estados Unidos, 27834
- Reclutamiento
- East Carolina University
-
Contacto:
- Site Public Contact
- Número de teléfono: 252-744-1015
- Correo electrónico: eubankss@ecu.edu
-
Investigador principal:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Reclutamiento
- Wake Forest University Health Sciences
-
Contacto:
- Site Public Contact
- Número de teléfono: 336-713-6771
-
Investigador principal:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58122
- Reclutamiento
- Sanford Broadway Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 701-323-5760
- Correo electrónico: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Investigador principal:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44308
- Reclutamiento
- Children's Hospital Medical Center of Akron
-
Contacto:
- Site Public Contact
- Número de teléfono: 330-543-3193
-
Investigador principal:
- Lauren R. Draper
-
Cincinnati, Ohio, Estados Unidos, 45229
- Reclutamiento
- Cincinnati Children's Hospital Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 513-636-2799
- Correo electrónico: cancer@cchmc.org
-
Investigador principal:
- Katherine M. Somers
-
Cleveland, Ohio, Estados Unidos, 44195
- Reclutamiento
- Cleveland Clinic Foundation
-
Contacto:
- Site Public Contact
- Número de teléfono: 866-223-8100
- Correo electrónico: TaussigResearch@ccf.org
-
Investigador principal:
- Matteo M. Trucco
-
Cleveland, Ohio, Estados Unidos, 44106
- Reclutamiento
- Rainbow Babies and Childrens Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 216-844-5437
-
Investigador principal:
- Duncan S. Stearns
-
Columbus, Ohio, Estados Unidos, 43205
- Reclutamiento
- Nationwide Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 614-722-6039
- Correo electrónico: Melinda.Triplet@nationwidechildrens.org
-
Investigador principal:
- Mark A. Ranalli
-
Dayton, Ohio, Estados Unidos, 45404
- Reclutamiento
- Dayton Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-228-4055
-
Investigador principal:
- Jordan M. Wright
-
Toledo, Ohio, Estados Unidos, 43606
- Reclutamiento
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 419-824-1842
- Correo electrónico: PCIOncResearch@promedica.org
-
Investigador principal:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Reclutamiento
- University of Oklahoma Health Sciences Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 405-271-8777
- Correo electrónico: ou-clinical-trials@ouhsc.edu
-
Investigador principal:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Estados Unidos, 74136
- Reclutamiento
- Saint Francis Children's Hospital
-
Investigador principal:
- Jill A. Salo
-
Contacto:
- Site Public Contact
- Número de teléfono: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97227
- Reclutamiento
- Legacy Emanuel Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 503-413-2560
-
Investigador principal:
- Jason M. Glover
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- Oregon Health and Science University
-
Contacto:
- Site Public Contact
- Número de teléfono: 503-494-1080
- Correo electrónico: trials@ohsu.edu
-
Investigador principal:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Reclutamiento
- Lehigh Valley Hospital-Cedar Crest
-
Contacto:
- Site Public Contact
- Número de teléfono: 610-402-9543
- Correo electrónico: Morgan_M.Horton@lvhn.org
-
Investigador principal:
- Jacob A. Troutman
-
Danville, Pennsylvania, Estados Unidos, 17822
- Reclutamiento
- Geisinger Medical Center
-
Investigador principal:
- Jagadeesh Ramdas
-
Contacto:
- Site Public Contact
- Número de teléfono: 570-271-5251
- Correo electrónico: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Children's Hospital of Philadelphia
-
Investigador principal:
- Rochelle Bagatell
-
Contacto:
- Site Public Contact
- Número de teléfono: 267-425-5544
- Correo electrónico: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Estados Unidos, 19134
- Reclutamiento
- Saint Christopher's Hospital for Children
-
Contacto:
- Site Public Contact
- Número de teléfono: 215-427-8991
-
Investigador principal:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Reclutamiento
- Children's Hospital of Pittsburgh of UPMC
-
Contacto:
- Site Public Contact
- Número de teléfono: 412-692-8570
- Correo electrónico: jean.tersak@chp.edu
-
Investigador principal:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Reclutamiento
- Rhode Island Hospital
-
Investigador principal:
- Bradley DeNardo
-
Contacto:
- Site Public Contact
- Número de teléfono: 401-444-1488
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Reclutamiento
- Medical University of South Carolina
-
Contacto:
- Site Public Contact
- Número de teléfono: 843-792-9321
- Correo electrónico: hcc-clinical-trials@musc.edu
-
Investigador principal:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, Estados Unidos, 29203
- Reclutamiento
- Prisma Health Richland Hospital
-
Investigador principal:
- Stuart L. Cramer
-
Contacto:
- Site Public Contact
- Número de teléfono: 864-522-4317
- Correo electrónico: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Estados Unidos, 29605
- Reclutamiento
- BI-LO Charities Children's Cancer Center
-
Investigador principal:
- Aniket Saha
-
Contacto:
- Site Public Contact
- Número de teléfono: 864-522-4317
- Correo electrónico: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57117-5134
- Reclutamiento
- Sanford USD Medical Center - Sioux Falls
-
Contacto:
- Site Public Contact
- Número de teléfono: 605-312-3320
- Correo electrónico: OncologyClinicalTrialsSF@SanfordHealth.org
-
Investigador principal:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37916
- Reclutamiento
- East Tennessee Childrens Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 865-541-8266
-
Investigador principal:
- Susan E. Spiller
-
Memphis, Tennessee, Estados Unidos, 38105
- Reclutamiento
- Saint Jude Children's Research Hospital
-
Investigador principal:
- Sara M. Federico
-
Contacto:
- Site Public Contact
- Número de teléfono: 888-226-4343
- Correo electrónico: referralinfo@stjude.org
-
Nashville, Tennessee, Estados Unidos, 37232
- Reclutamiento
- Vanderbilt University/Ingram Cancer Center
-
Investigador principal:
- Daniel J. Benedetti
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-811-8480
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- The Children's Hospital at TriStar Centennial
-
Contacto:
- Site Public Contact
- Número de teléfono: 615-342-1919
-
Investigador principal:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Estados Unidos, 78723
- Reclutamiento
- Dell Children's Medical Center of Central Texas
-
Contacto:
- Site Public Contact
- Número de teléfono: 512-628-1902
- Correo electrónico: TXAUS-DL-SFCHemonc.research@ascension.org
-
Investigador principal:
- Shannon M. Cohn
-
Corpus Christi, Texas, Estados Unidos, 78411
- Reclutamiento
- Driscoll Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 361-694-5311
- Correo electrónico: Crystal.DeLosSantos@dchstx.org
-
Investigador principal:
- Nkechi I. Mba
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Investigador principal:
- Tanya C. Watt
-
Contacto:
- Site Public Contact
- Número de teléfono: 214-648-7097
- Correo electrónico: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, Estados Unidos, 75230
- Reclutamiento
- Medical City Dallas Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 972-566-5588
-
Investigador principal:
- Maurizio L. Ghisoli
-
El Paso, Texas, Estados Unidos, 79905
- Reclutamiento
- El Paso Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 915-298-5444
- Correo electrónico: ranjan.bista@ttuhsc.edu
-
Investigador principal:
- Benjamin Carcamo
-
Fort Worth, Texas, Estados Unidos, 76104
- Reclutamiento
- Cook Children's Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 682-885-2103
- Correo electrónico: CookChildrensResearch@cookchildrens.org
-
Investigador principal:
- Chelsee Greer
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 713-798-1354
- Correo electrónico: burton@bcm.edu
-
Investigador principal:
- Jennifer H. Foster
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- UT MD Anderson Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 866-632-6789
- Correo electrónico: askmdanderson@mdanderson.org
-
Investigador principal:
- Najat C. Daw
-
Lubbock, Texas, Estados Unidos, 79410
- Reclutamiento
- Covenant Children's Hospital
-
Investigador principal:
- Kishor M. Bhende
-
Contacto:
- Site Public Contact
- Número de teléfono: 806-725-8657
- Correo electrónico: mbisbee@providence.org
-
Lubbock, Texas, Estados Unidos, 79415
- Reclutamiento
- UMC Cancer Center / UMC Health System
-
Contacto:
- Site Public Contact
- Número de teléfono: 806-775-8590
-
Investigador principal:
- Erin K. Barr
-
San Antonio, Texas, Estados Unidos, 78207
- Reclutamiento
- Children's Hospital of San Antonio
-
Contacto:
- Site Public Contact
- Número de teléfono: 210-704-2894
- Correo electrónico: bridget.medina@christushealth.org
-
Investigador principal:
- Julie Voeller
-
San Antonio, Texas, Estados Unidos, 78229
- Reclutamiento
- University of Texas Health Science Center at San Antonio
-
Contacto:
- Site Public Contact
- Número de teléfono: 210-450-3800
- Correo electrónico: phoresearchoffice@uthscsa.edu
-
Investigador principal:
- Aaron J. Sugalski
-
San Antonio, Texas, Estados Unidos, 78229
- Reclutamiento
- Methodist Children's Hospital of South Texas
-
Contacto:
- Site Public Contact
- Número de teléfono: 210-575-6240
- Correo electrónico: Vinod.GidvaniDiaz@hcahealthcare.com
-
Investigador principal:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Reclutamiento
- Primary Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 801-585-5270
-
Investigador principal:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05405
- Reclutamiento
- University of Vermont and State Agricultural College
-
Contacto:
- Site Public Contact
- Número de teléfono: 802-656-8990
- Correo electrónico: rpo@uvm.edu
-
Investigador principal:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- Reclutamiento
- University of Virginia Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 434-243-6303
- Correo electrónico: uvacancertrials@hscmail.mcc.virginia.edu
-
Investigador principal:
- Brian C. Belyea
-
Portsmouth, Virginia, Estados Unidos, 23708-2197
- Reclutamiento
- Naval Medical Center - Portsmouth
-
Contacto:
- Site Public Contact
- Número de teléfono: 757-953-5939
-
Investigador principal:
- Karin Brockman
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Reclutamiento
- Seattle Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 866-987-2000
-
Investigador principal:
- Sarah E. Leary
-
Spokane, Washington, Estados Unidos, 99204
- Reclutamiento
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-228-6618
- Correo electrónico: HopeBeginsHere@providence.org
-
Investigador principal:
- Judy L. Felgenhauer
-
Tacoma, Washington, Estados Unidos, 98405
- Reclutamiento
- Mary Bridge Children's Hospital and Health Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 253-403-1461
- Correo electrónico: research@multicare.org
-
Investigador principal:
- Robert G. Irwin
-
-
West Virginia
-
Huntington, West Virginia, Estados Unidos, 25701
- Reclutamiento
- Edwards Comprehensive Cancer Center
-
Investigador principal:
- Mark A. Ranalli
-
Contacto:
- Site Public Contact
- Número de teléfono: 304-399-6566
- Correo electrónico: Christina.Cole@chhi.org
-
Morgantown, West Virginia, Estados Unidos, 26506
- Reclutamiento
- West Virginia University Healthcare
-
Contacto:
- Site Public Contact
- Número de teléfono: 304-293-7374
- Correo electrónico: cancertrialsinfo@hsc.wvu.edu
-
Investigador principal:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay, Wisconsin, Estados Unidos, 54301
- Suspendido
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Estados Unidos, 53792
- Reclutamiento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-622-8922
- Correo electrónico: clinicaltrials@cancer.wisc.edu
-
Investigador principal:
- Margo L. Hoover-Regan
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Reclutamiento
- Marshfield Medical Center-Marshfield
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-782-8581
- Correo electrónico: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Children's Hospital of Wisconsin
-
Investigador principal:
- Angela Steineck
-
Contacto:
- Site Public Contact
- Número de teléfono: 414-955-4727
- Correo electrónico: MACCCTO@mcw.edu
-
-
-
-
Auckland
-
Grafton, Auckland, Nueva Zelanda, 1145
- Reclutamiento
- Starship Children's Hospital
-
Investigador principal:
- Andrew C. Wood
-
Contacto:
- Site Public Contact
- Número de teléfono: 0800 728 436
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Reclutamiento
- University Pediatric Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 787-474-0333
-
Investigador principal:
- Maria E. Echevarria
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Arm A (SOC treatment)
See detailed description |
Given IV
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo bone marrow biopsy
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo MRI
Otros nombres:
Undergo ECHO
Otros nombres:
Undergo MUGA
Otros nombres:
Undergo bone marrow aspiration Given IV
Otros nombres:
Undergo CT scan
Otros nombres:
Given IV
Otros nombres:
Undergo radiation therapy
Otros nombres:
Undergo blood and urine sample collection
Otros nombres:
Ancillary studies Given IV
Otros nombres:
Given IV Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo FDG PET
Otros nombres:
Undergo stem cell infusion
Otros nombres:
Given PO
Otros nombres:
Undergo apheresis
Otros nombres:
Undergo I-MIBG scan
Otros nombres:
Given PO or via NG or G tube
Otros nombres:
Undergo tumor resection surgery |
|
Experimental: Arm B (Dinutuximab in induction)
See detailed description |
Given IV
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo bone marrow biopsy
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo MRI
Otros nombres:
Undergo ECHO
Otros nombres:
Undergo MUGA
Otros nombres:
Undergo bone marrow aspiration Given IV
Otros nombres:
Undergo CT scan
Otros nombres:
Given IV
Otros nombres:
Undergo radiation therapy
Otros nombres:
Undergo blood and urine sample collection
Otros nombres:
Ancillary studies Given IV
Otros nombres:
Given IV Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo FDG PET
Otros nombres:
Undergo stem cell infusion
Otros nombres:
Given PO
Otros nombres:
Undergo apheresis
Otros nombres:
Undergo I-MIBG scan
Otros nombres:
Given PO or via NG or G tube
Otros nombres:
Undergo tumor resection surgery |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Event free survival (EFS)
Periodo de tiempo: Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
End of Induction (EOI) response rate
Periodo de tiempo: From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
Periodo de tiempo: Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
Periodo de tiempo: Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
Periodo de tiempo: Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Association between tumor and host factors and outcomes
Periodo de tiempo: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
Periodo de tiempo: Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
Periodo de tiempo: Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
Periodo de tiempo: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
Periodo de tiempo: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
Periodo de tiempo: At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
Periodo de tiempo: Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
Periodo de tiempo: At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
Periodo de tiempo: Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
Periodo de tiempo: Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
Periodo de tiempo: Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
Periodo de tiempo: Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
Periodo de tiempo: Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
Periodo de tiempo: Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Sara M Federico, Children's Oncology Group
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Neoplasias Neuroepiteliales
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores Neuroectodérmicos Primitivos Periféricos
- Tumores Neuroectodérmicos Primitivos
- Neuroblastoma
- Ganglioneuroblastoma
- Organización y administración
- Administración de Servicios de Salud
- Aminoácidos, péptidos y proteínas
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Técnicas de investigación
- Terapéutica
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Procedimientos quirúrgicos, operativo
- Azoles
- Técnicas citológicas
- Citodiagnóstico
- Retinoides
- Carotenoides
- Polenes
- Álcenos
- Hidrocarburos, acíclico
- Hidrocarburos
- Ciclohexenos
- Ciclohexanos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Pigmentos, biológico
- Factores biológicos
- Carbohidratos
- Fenómeno físico
- Campeptecina
- Alcaloides
- Podoflotoxina
- Tetrahidronaftalenos
- Naftalenos
- Hidrocarburos aromáticos policíclicos
- Hidrocarburos, aromáticos
- Compuestos policíclicos
- Glucósidos
- Glucósidos
- Dacarbazina
- Triazenes
- Imidazoles
- Trasplante
- Indoles
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Complejos de coordinación
- Aminoácidos
- Elementos
- Rieles
- Técnicas de diagnóstico, quirúrgico
- Técnicas de química, analítica
- Análisis de espectro
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Metales, pesado
- Alcaloides de Vinca
- Alcaloides de triptamina de secologanina
- Alcaloides de indol
- Indolizidinas
- Indolizinas
- Antraciclinas
- Naftacenos
- Aminoglucósidos
- Compuestos de platino
- Daunorrubicina
- Elementos de transición
- Trasplante de células
- Terapia basada en células y tejidos
- Terapia biológica
- Citaféresis
- Extracción de componentes sanguíneos
- Procedimientos de reducción de leucocitos
- Separación celular
- Fenilalanina
- Aminoácidos, aromáticos
- Aminoácidos, cíclico
- Administración hospitalaria
- Administración de instalaciones de salud
- Trietilenefosforamida
- Aziridinas
- Azirines
- Procedimientos quirúrgicos urológicos
- Procedimientos quirúrgicos urogenitales
- Temozolomida
- Irinotecán
- Ciclofosfamida
- Melfalán
- Etopósido
- Carboplatino
- Doxorrubicina
- Vincristina
- Cisplatino
- Isotretinoína
- Tiotepa
- Topotecán
- Citrato de 1,2-diaminociclohexanoplatino II
- Radioterapia
- Radiación
- Biopsia
- Manejo de muestras
- Espectroscopía de resonancia magnética
- Platino
- dinutuximab
- Trasplante de células madre
- Trasplante de células madre hematopoyéticas
- Leucaféresis
- Departamento de medicina nuclear, hospital
- Resección transuretral de la vejiga
Otros números de identificación del estudio
Otros números de identificación del estudio
- NCI-2023-08530
- U10CA180886 (Subvención/contrato del NIH de EE. UU.)
- NCI-2023-08530 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- ANBL2131 (Otro identificador: CTEP)
- ANBL2131 (Otro identificador: Children's Oncology Group)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .